

## Variations Addendum

28 September 2020

### Interim measures pending update of Variations Addendum

Dear Industry colleagues,

Please be advised that the Variations addendum (*2.08\_Variations Addendum for Human and Veterinary Medicines\_June2020\_v1.docx*) has been withdrawn on 1<sup>st</sup> September 2020 from the SAHPRA website for updates to some general aspects including administrative and quality variation coding.

An Interim guidance namely, *2.08a\_Interim Variations Addendum for Human and Veterinary Medicines\_September2020\_v1.docx* will be uploaded as the interim measure until the revised guidance is accepted for implementation.

The Interim guideline reverts the below listed Quality variation coding to the EMA variation classification. The proposed Inspectorate timelines of 60 days will be revisited within 12 months from implementation. The interim guideline also includes the update on the interpretation of Quality Variation Type II fees.

Please note that the Clinical, amendments will not be affected and that these will remain essentially unchanged from the *2.08\_Variations Addendum for Human and Veterinary Medicines\_June2020\_v1*.

#### List of Quality Variation codes

SAHPRA/EMA code	Code description	EMA/SAHPRA Classification
B.I.a.1a	The proposed manufacturer is part of the same pharmaceutical group as the currently approved manufacture	Type IA <sub>IN</sub>
B.I.a.2a	Minor change in the manufacturing process of the active substance	Type IA
B.I.a.3a	Up to 10-fold increase compared to the originally approved batch size	Type IA
B.I.a.3d	More than 10-fold increase compared to the originally approved batch size	Type IB
B.II.a.3b1	Any minor adjustment of the quantitative composition of the finished product with respect to excipients	Type IA
B.II.b.3a	Minor change in the manufacturing process	Type IA
B.II.b.4a	Up to 10-fold compared to the originally approved batch size	Type IA

B.II.b.4e	More than 10-fold increase Type IA <sub>IN</sub> compared to the originally approved batch size for immediate release (oral) pharmaceutical forms	Type IB
B.III.1a3	New certificate of suitability (CEP) from a new manufacturer (replacement or addition)	Type IA <sub>IN</sub>

**List of Inspectorate quality codes**

Code	Classification	Timeline required	Description of change
B.II.b.1.b	IA <sub>in</sub>	60 days	Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Primary packaging site
B.II.b.1.e	IB	60 days	Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Site where any manufacturing operation(s) take place, except batch-release, batch control, primary and secondary packaging, for non-sterile medicinal products
B.II.b.1.f	IB	60 days	Replacement or addition of a manufacturing site for part or all of the manufacturing process of the finished product - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for sterile medicinal products (including those that are aseptically manufactured) excluding biological/immunological medicinal products

Applicants are advised that the alteration for the above mentioned codes is a temporary alteration which SAHPRA commit to revisit within 12 months.

Applicants who have already prepared quality variations for submission based on the *2.08\_Variations Addendum for Human and Veterinary Medicines\_June2020\_v1.docx* guidance may wish to reconsider submission based on the above.

Applicants are advised that variations submitted as Type 1A and Type IA<sub>in</sub> (whilst implemented or implementable) should receive a response from SAHPRA within 30 days of the date of submission of these notifications in line with EMA guideline for submission of notifications. No communication from SAHPRA following the 30-day notification period implies that the implementation of the notification is accepted.

For any further enquiries on the above please contact [silverani.padayachee@sahpra.org.za](mailto:silverani.padayachee@sahpra.org.za)